Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | STING1 | Q86WV6 | 12/20 | 0.46 |
| ▸ | HINT1 | P49773 | 1/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17359805 | 0.90 | ADORA3 (0.52) | ADORA3STING1HINT1PDE3BPDE3A | |
| SCHEMBL16373915 | 0.90 | ADORA3 (0.52) | ADORA3STING1HINT1PDE3BPDE3A | |
| SCHEMBL25581273 | 0.90 | ADORA3 (0.47) | ADORA3STING1HINT1PDE3BPDE3A | |
| SCHEMBL25397152 | 0.89 | ADORA3 (0.52) | ADORA3STING1HINT1PDE3BPDE3A | |
| SCHEMBL16373907 | 0.89 | ADORA3 (0.47) | ADORA3STING1HINT1PDE3BPDE3A | |
| SCHEMBL19993713 | 0.89 | ADORA3 (0.47) | ADORA3STING1HINT1PDE3BPDE3A | |
| SCHEMBL15070633 | 0.89 | ADORA3 (0.51) | ADORA3STING1HINT1PDE3BPDE3A | |
| SCHEMBL25400949 | 0.89 | ADORA3 (0.51) | ADORA3STING1HINT1PDE3BPDE3A | |
| SCHEMBL25401067 | 0.89 | ADORA3 (0.51) | ADORA3STING1HINT1PDE3BPDE3A | |
| SCHEMBL15075451 | 0.89 | ADORA3 (0.51) | ADORA3STING1HINT1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Biopharma, Inc. | 2017-05-25 | — | — | US | disclosed |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170143749-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, TYMP | ADORA3 83/4885STING1 280/4885HINT1 74/4885 |
| US-20170143751-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | ADORA3 79/4885STING1 255/4885HINT1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.